Benzodiazepines Remain Important Therapeutic Options in Psychiatric Practice
The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Abstract
Benzodiazepines and medications acting on benzodiazepine receptors that do not have a benzodiazepine structure (z-drugs) have been viewed by some experts and regulatory bodies as having limited benefit and significant risks. Data presented in this article support the use of these medications as treatments of choice for acute situational anxiety, chronic anxiety disorders, insomnia, alcohol withdrawal syndromes, and catatonia. They may also be useful adjuncts in the treatment of anxious depression and mania, and for medically ill patients. Tolerance develops to sedation and possibly psychomotor impairment, but not to the anxiolytic effect of benzodiazepines. Sedation can impair cognitive function in some patients, but assertions that benzodiazepines increase the risk of dementia are not supported by recent data. Contrary to popular opinion, benzodiazepines are not frequently misused or conduits to misuse of other substances in patients without substance use disorders who are prescribed these medications for appropriate indications; most benzodiazepine misuse involves medications that are obtained from other people. Benzodiazepines are usually not lethal in overdose except when ingested with other substances, especially alcohol and opioids. Benzodiazepines comprise one of the few classes of psychotropic medication the mechanisms of action of which are clearly delineated, allowing for greater precision in their clinical use. These medications, therefore, belong in the therapeutic armamentarium of the knowledgeable clinician.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After several decades of use, Benzodiazepines and Benzodiazepine Receptor Agonists remain important therapeutic options for the treatment of mental health related concerns such as anxiety and sleep disorders.1”
Citations
Cites
Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519
Penninx, B. W., Pine, D. S., Holmes, E. A., & Reif, A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00359-7 · Cited by 740
Tromp, A. M., Pluijm, S. M. F., Smit, J. H., Deeg, D. J. H., Bouter, L. M., & Lips, P. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00349-3 · Cited by 666
Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy
Geffrey, A. L., Pollack, S. F., Bruno, P. L., & Thiele, E. A. (2015) · Epilepsia · doi:10.1111/epi.13060 · Cited by 496
Slee, A., Nazareth, I., Bondaronek, P., Liu, Y., Cheng, Z., & Freemantle, N. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31793-8 · Cited by 372
Withdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369
Dolovich, L. R., Addis, A., Vaillancourt, J. M. R., Power, J. D. B., Koren, G., & Einarson, T. R. (1998) · BMJ · doi:10.1136/bmj.317.7162.839 · Cited by 353
The Pharmacologic Treatment of Anxiety Disorders: A Review of Progress
Ravindran, L. N., & Stein, M. B. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06218blu · Cited by 317
Paradoxical reactions to benzodiazepines: literature review and treatment options
Mancuso, C. E., Tanzi, M. G., & Gabay, M. (2004) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.13.1177.38089 · Cited by 298
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Research works printed but not linked: 1
- 10.1080/15622975.2018.1500031 · DOI · Paper page
Cited by
Hirjak, D., Rogers, J. P., Wolf, R. C., Kubera, K. M., Fritze, S., Wilson, J. E., Sambataro, F., Fricchione, G. L., Meyer‐Lindenberg, A., Ungvari, G. S., et al. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00534-w · Cited by 106
Mitochondrial dysfunction and neurological disorders: A narrative review and treatment overview
Alshial, E. E., Abdulghaney, M. I., Wadan, A. S., Abdellatif, M. A., Ramadan, N. E., Suleiman, A. M., Waheed, N., Abdellatif, M., & Mohammed, H. S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122257 · Cited by 98
Brandt, J., Bressi, J., Lê, M.-L., Neal, D., Cadogan, C., Witt-Doerring, J., Witt-Doerring, M., & Wright, S. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102507 · Cited by 77
Huang, J., Huang, W., Yi, J., Deng, Y., Li, R., Chen, J., Shi, J., Qiu, Y., Wang, T., Chen, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43150-0 · Cited by 81
Ngcobo, N. N. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01466-0 · Cited by 199
Metadata
- Authors
- Dubovsky, S. L., & Marshall, D.
- Affiliations
- University of Colorado Anschutz (US)
- University at Buffalo, State University of New York (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2022
- Volume
- 91
- Issue
- 5
- Pages
- 307-334
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W4225388848
- Cited by
- 171
- References
- 105
- Citations by year
- 2026: 40 · 2025: 44 · 2024: 41 · 2023: 38 · 2022: 8
- FWCI
- 4.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and pharmacology of benzodiazepine derivatives
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- benzodiazepines, Z-drugs, anxiety disorders, insomnia, alcohol withdrawal, catatonia, anxious depression, mania, sedation, tolerance (pharmacology and immunology), cognitive impairment, dementia risk, benzodiazepine misuse, benzodiazepine overdose, benzodiazepine receptor, mechanism of action
- MeSH terms
- Alcoholism, Anxiety, Benzodiazepines, Humans, Substance Withdrawal Syndrome, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benzodiazepines Remain Important Therapeutic Options in Psychiatric Practice. https://app.cochat.ai/papers/10.1159/000524400
- The paper
- Dubovsky, S. L., & Marshall, D. (2022). Benzodiazepines Remain Important Therapeutic Options in Psychiatric Practice. Psychotherapy and Psychosomatics. https://doi.org/10.1159/000524400
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.